Profit-taking sinks MediciNova, down 15%

• Thinly traded micro cap MediciNova (NASDAQ:MNOV -14.5%) slips on more than double normal volume, albeit on turnover of only 160K shares, in apparent profit-taking after its 60% runup since mid-August.
• On October 28, data from a mid-stage study of ibudilast (MN-166) in progressive multiple sclerosis will be presented at the Joint ECTRIMS-ACTRIMS Meeting in Paris, France.
• Previously: MediciNova's mid-stage study of MN-166 in progressive MS to continue as planned (Dec. 19, 2016)